SUMO2 and neoplasm: By measuring SAE2 proteins in tumor lysates, we observed that Dox treated SAE2 shRNA tumors have a decreased level of SAE2, associated with lower levels of UBC9-SUMO thioester and SUMO2/3 conjugates (Fig 6B), suggesting a functional SUMO inhibition in vivo by our approach.